|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�鰷H1���� |
|
����,�鰷 |
| ��������������� | |
|
��ѧ�� |
|
���� |
| PubMed | |
|
Article by WAN Xue-feng |
|
Article by HUI Yan |
H1���鰷ҩ���о���չ
��ѧ��, ����
�½�ҽ�ƴ�ѧ��һ�ٴ�ҽԺƤ���� ��³ľ�� 830054
�������鰷������Ҫ��H1��H2��H3��H4������������,�鰷��Ҫͨ�����巢������ѧ���á�ĿǰH1���鰷ҩ����Ҫ��������ݡ������������Լ���,������ϵͳ������ǰͥ��������һ��H1���鰷ҩ���������ƹ����Լ������淶���о�,�����ٴ����鲻���ϵ�ǰ���˫ä��������ı�����֮���,�ڶ���H1���鰷ҩ����д�����ֵ�����֧�֡��ٴ��ϴ�H1���鰷ҩ�ﰲȫ��Ч,����������ϵͳ������IJ�����Ӧ���ݺ��ӡ�
Advances in H1-antihistamines
Department of Dermatology, First Hospital of Xinjiang Medical University, Urumqi 830054, China
Department of Dermatology, First Hospital of Xinjiang Medical University, Urumqi 830054, China
There are four major types of histamine receptor,H1,H2,H3 and H4 in human body. Histamine plays its biologic role primarily through its receptors. At present,H1-antihistamines are mainly used to treat urticaria and other allergic diseases as well as central nervous system and vestibular disorders. There has never been standardized studies on the application of first-generation H1-antihistamines in the treatment of allergic diseases, and most clinical trials of these drugs do not meet the standards for randomized, double-blind,placebo-controlled trial (RCT). In contrast, the second-generation drugs are supported by large number of normative trials. Clinically, most H1-antihistamines are safe and effective, but the side effects on central nervous system and the heart should not be ignored.
[2] Banu Y,Watanabe T.Augmentation of antigen receptor-mediated responses by histamine H1 receptor signaling.J Exp Med,1999,189:673-682.
[3] Yanai K,Son LZ,Endou M,et al.Targeting disruption of histamine H1 receptors in mice:behavioral and neurochemical characterization.Life Sci,1998,62:1607-1610.
[4] Shamsi Z,Hindmarch I.Sedation and antihistamines:a review of inter-drug differences using proportional impairment ratios.Hum Psychopharmacol,2000,15(Suppl 1):S3-S30.
[5] Reimers A,Hari Y,Muller U.Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine:a double-blind,placebo-controlled trial.Allergy,2000,55:484-488.
[6] Kawashima M,Tango T,Noguchi T,et al.Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized,multicentre,double-blind,placebo-controlled,parallel-group study.Br J Dermatol,2003,148:1212-1221.
[7] Diepgen TL.Long-term treatment with cetirizine of infants with atopic dermatitis:a multi-country,double-blind,randomized,placebo-controlled trial (the ETAC trial) over 18 months.Pediatr Allergy Immuno,2002,13:278-286.
[8] Karppinen A,Kautiainen H,Petman L,et al.Comparison of cetirizine,ebastine and loratadine in the treatment of immediate mosquito-bite allergy.Allergy,2002,57:534-537.
[9] Timmerman H.Factors involved in the absence of sedative effects by the second-generation antihistamines.Allergy,2000,55(Suppl 60):5-10.
[10] Chishty M,Reichel A,Siva J,et al.Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modem antihistamines.J Drug Target,2001,9:223-228.
[11] Chen C,Hanson E,Watson JW,et al.P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.Drug Metab Dispos,2003,31:312-318.
[12] Cobb DB,Watson WA,Fernandez MC.High-dose loratadine exposure in a six-year-old child.Vet Hum Toxicol,2001,43:163-164.
[13] Spiller HA,Villalobos D,Benson BE,et al.Retrospective evaluation of cetirizine (zyrtec) ingestion.J Toxicol Clin Toxicol,2002,40:525-526.
[14] Weiler JM,Bloomfield JR,Woodworth GG,et al.Effects of fexofenadine,diphenhydramine,and alcohol on driving performance.A randomized,placebo-controlled trial in the Iowa driving simulator.Ann Intern Med,2000,132:354-363.
[15] De Bruin ML,van Puijenbroek EP,Egberts AC,et al.Non-sedating antihistamine drugs and cardiac arrhythmias --biased risk estimates from spontaneous reporting systems? Br J Clin Pharmacol,2002,53:370-374.